Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus AVD vs Brentuximab Vedotin Plus AVD in Advanced Stage Classical Hodgkin Lymphoma
NCT03907488Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of nivolumab, brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by National Cancer Institute. Started Aug 2019; status: active, not recruiting.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03907488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907488.